CEO Brings Extensive Biotechnology, Medical Technology Commercialization and Diagnostics Expertise
MADISON, Wis.–(BUSINESS WIRE)–OpGen, Inc., a leader in single molecule DNA analysis, today announced that Noel Doheny has joined OpGen as the Chief Executive Officer and a member of OpGen’s Board of Directors. Mr. Doheny brings over 30 years of experience leading and growing both publicly traded and start-up health care and biotechnology businesses. Most recently he led the diagnostic efforts at Affymetrix, where he was Senior Vice President of Molecular Diagnostics.
“Noel was the perfect choice to lead OpGen through our next phase of growth,” said Ron Lennox, Chairman of the Board of OpGen and partner at the investment firm CHL Medical Partners. “In addition to bringing a unique combination of market, strategic and commercial leadership to the company, Noel’s expertise in diagnostics and emerging technologies in genetics, medical devices and health care, and his skills in technology commercialization will be invaluable to OpGen.”
OpGen, Inc. delivers breakthrough capabilities to identify microorganisms using a unique method to analyze DNA extracted directly from microbial cells. “Optical Mapping” has been used by organizations worldwide for comparative genomic analysis of a range of organisms of importance to human health.
Prior to joining OpGen, Mr. Doheny has held leadership roles at Ciba-Corning (now Siemens), Biostar (now Inverness Medical) and Qiagen. In each role, Mr. Doheny was able to identify opportunities to apply existing technologies to solve diagnostic measurement needs in blood chemistry, coagulation, rapid infectious disease detection and nucleic acid sample preparation.
“Optical Mapping is an incredibly flexible technology that can be applied to a variety of microbial analytical challenges including sequencing, strain identification, as well as pathogen resistance analysis. By delivering Mapping solutions, in service and product formats, OpGen can dramatically impact the field of infectious disease management. I believe that there is a dramatic upside to Optical Mapping in the coming years,” Doheny added.
About OpGen
OpGen is commercializing a novel single molecule DNA analysis technology, “Optical Mapping”, for rapid identification and analysis of microorganisms. The system can be used to obtain detailed genetic information with no requirement for prior sequence data, PCR, cloning or probes. Applications of the new commercial systems include clinical microbial analysis, forensic microbiology and the development of novel molecular diagnostic products. OpGen’s investor’s include CHL Medical, Highland Capital Partners, Versant Ventures, In-Q-Tel and Mason Wells. For more information, please visit www.opgen.com or call 608-441-8100.
